Iambic Reports Durable Responses to IAM1363 in Phase 1/1b Cancer Trial

• Iambic Therapeutics presented updated Phase 1/1b results for HER2 inhibitor IAM1363 at ESMO in Madrid on October 23, 2026.
• Treatment showed durable tumor responses across HER2-altered advanced cancers in heavily pretreated participants.
• Brain metastases shrank in some breast cancer participants previously treated with trastuzumab deruxtecan and tucatinib.
• IAM1363 was generally well tolerated at the recommended dose, with few severe treatment-related adverse events.
• Enrollment continues in monotherapy expansion and combination cohorts across the U.S., Europe and Asia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iambic Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026425956) on October 26, 2026, and is solely responsible for the information contained therein.